GeneLancet Biosciences

Biotechnology Research • Buckingham, Pennsylvania, United States • 1-10 Employees

Company overview

Headquarters	3805 Old Easton Rd, Doylestown, Pennsylvania 18902, US
Phone number	+15182532778
Website	genelancetbio.com
NAICS	541714
Employees	1-10
Socials

Key Contact at GeneLancet Biosciences

Minghong Zhong

Chief Executive Officer

About GeneLancet Biosciences

GeneLancet, a gene editing company, owns a novel lgRNA-guided gene editing platform for developing cures for chronic HBV, HIV and monogenic diseases such as Cystic Fibrosis and Alzheimer’s disease. Guide RNA directs where CRISPR cuts. lgRNA is a single-molecule guide RNA of distinct intellectual property for CRISPR gene editors. lgRNA comprises our proprietary non-nucleotide linkers designed for efficient synthesis of modified guide RNAs and RNP conjugates for cell-targeted efficient, accurate, precise, and multiple dosing gene editing. lgRNA technology makes cost-effective and robust production of consistent high-quality single-molecule guide RNAs our routine practice. We provide CRISPR-Cas/lgRNA and its conjugates as useful gene-manipulation tools, and its high-quality arrayed libraries for genomic screenings. Visit us at: GeneLancet Biosciences, Inc. 3805 Old Easton Road, Doylestown, PA 18902 https://www.genelancetbio.com Email: info@genelancetbio.com

GeneLancet Biosciences revenue & valuation

Annual revenue	$171,110
Revenue per employee	$86,000
Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues	$547,552
Total funding	No funding

Employees by Management Level

Total employees: 1-10

Seniority

Employees

C-Suite

Employees by Department

GeneLancet Biosciences has 1 employees across 1 departments.

Departments

Number of employees

Funding Data

Explore GeneLancet Biosciences's funding history, including investment rounds, total capital raised, and key backers.

Funding Date	Round	Amount	Link to Article
2019-12-04	2	N/A

Funding Insights

Number of funding rounds